Application of ritonavir in preparing medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

A technology for ritonavir and pulmonary fibrosis, applied in the field of application of ritonavir in the preparation of drugs for the prevention or treatment of acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis, can solve the pharmacological effects that have not been seen Reporting, slowing the spread of HIV, and more

Inactive Publication Date: 2014-10-01
BINZHOU MEDICAL COLLEGE
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Clinically, ritonavir mainly treats adult HIV-I infection, and is an oral effective inhibitor of human immunodeficiency virus-1 (HIV-1) and human immunodeficiency virus-2 (HIV-2) aspartic acid protease, blocking the The enzyme promotes the production of polyproteins required for morphologically mature HIV particles, so that HIV particles remain in an immature state, thereby slowing down the spread of HIV in cells to prevent the occurrence of new rounds of infection and delay the development of the disease, However, the pharmacological effects of ritonavir in the prevention or treatment of ALI / ARDS and pulmonary fibrosis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ritonavir in preparing medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of ritonavir in preparing medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of ritonavir in preparing medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0012] Embodiment 2 Ritonavir tablet preparation

[0013] Weigh 100.0g ritonavir and 100.0g carboxymethyl starch sodium, mix well and pass through a 100 mesh sieve, add an appropriate amount of 3% PVP k30 Appropriate amount of water solution to make soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, granulate with 18-mesh sieve, add 2.0g of magnesium stearate, mix well and press into tablets, adjust the weight of the tablet to about 200mg.

experiment example 2

[0025]Experimental example 2 Effect of ritonavir on acute lung injury / acute respiratory distress syndrome (ALI / ARDS) model rats caused by cecal ligation and perforation

[0026] 2.1 Drugs and reagents

[0027] Ritonavir (purity 99.5%, purchased from Dalian Meilun Biotechnology Co., Ltd.)

[0028] Limulus reagent kit (Fuzhou Xinbei Biochemical Industry Co., Ltd., Fujian Province, batch number: 080430)

[0029] Anti-Aquaporin5 antibody (abcam company, ab104751)

[0030] RAGE primary antibody was purchased from Sigma.

[0031] Experimental animals: SPF grade Sprague Dawley rats, male, weighing 150g-200g, provided by the Experimental Animal Center of Shandong Luye Pharmaceutical Co., Ltd., the animal qualification certificate number is: SYXK (Lu) 20030020.

[0032] 2.2 Experimental methods and results

[0033] 2.2.1 Preparation of rats with cecal ligation and puncture (CLP)

[0034] On the day of the operation, the rats were fasted in the morning, placed in the supine positio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a new medical application of ritonavir and in particular relates to an application of the ritonavir for preventing or treating Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) and pulmonary fibrosis in such a manner of inhibiting the occurrence and development of the ALI/ARDS and the pulmonary fibrosis by inhibiting the apoptosis of type I alveolar epithelial cells and promoting the expression of the Receptor For Advanced Glycation Endproducts (RAGE) of the type I alveolar epithelial cells. When in use, the oral administration dosage of the ritonavir ranges from 100mg to 6000mg, preferably, from 200mg to 3000mg.

Description

technical field [0001] The present invention relates to that ritonavir suppresses the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis so as to prevent or treat ALI / ARDS and pulmonary fibrosis; Specifically relate to ritonavir by inhibiting I Type I alveolar epithelial cell apoptosis, promote the expression of receptor for advanced glycation endproducts (RAGE) in type I alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute lung injury / acute respiratory distress syndrome (ALI / ARDS) is a common critical illness with a high mortality rate, which seriously threatens the life of critically ill patients and affects their quality of life. ALI / ARDS is acute hypoxic respiratory function caused by diffuse pulmonary interstitial and alveolar edema caused by damage to pulmonary capillary endothelial cells and alveolar epithelial cells during non-cardio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/427A61P11/00
Inventor 蒋王林纪云霞亢泽春吕长俊
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap